Clinical Trials Logo
  1. Home
  2. Benign Prostatic Hyperplasia
  3. NCT03167294
  4. Details
NCT03167294 Clinical Trial

AQUABEAM India Study for the Treatment of Benign Prostatic Hyperplasia

Benign Prostatic Hyperplasia Clinical Trial

— ABS  

Official title:
PROCEPT AQUABEAM Study for the Treatment of Benign Prostatic Hyperplasia (ABS)

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT03167294
Other study ID # TP0032
Secondary ID
Status Completed
Phase N/A
First received December 11, 2014
Last updated November 13, 2017
Start date December 14, 2014
Est. completion date April 27, 2017

Study information
Verified date November 2017
Source PROCEPT BioRobotics
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Single-arm prospective, interventional clinical trial. Results will be compared to a historical control in the treatment of benign prostatic hyperplasia

Recruitment information / eligibility
Status Completed
Enrollment 47
Est. completion date April 27, 2017
Est. primary completion date June 30, 2016
Accepts healthy volunteers No
Gender Male
Age group 50 Years to 80 Years
Eligibility Inclusion Criteria:

- Male

- 50 - 80 years

- Moderate to severe BPH

- Subjects who have failed standard medical therapy

Exclusion Criteria:

- Size and width of prostate

- Medical condition or co-morbidities where BPH intervention would be contraindicated

Study Design

Related Conditions & MeSH terms

Intervention

Device:
• AquaBeam System
Aquablation

Locations
Country Name City State
India Muljibhai Patel Urological Hospital Nadiad Gujarat

Sponsors (1)
Lead Sponsor Collaborator
PROCEPT BioRobotics

Country where clinical trial is conducted

India, 

Outcome
Type Measure Description Time frame Safety issue
Primary Primary Device Performance Endpoint The primary device performance endpoint is completion of the intended surgical procedure. 6 months
Primary Primary Safety Endpoint of the study is the perioperative complication rate. The primary safety endpoint of the study is the perioperative complication rate 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT04807296 - Thulium Fiber Laser Enucleation of the Prostate (TFLEP) vs HoLEP With Moses Technology (m-HoLEP) N/A
Recruiting NCT05574244 - Comparison of Functional Outcomes of Ejaculation-preserving Partial Trans Urethral Resection of the Prostate With Complete Trans Urethral Resection of the Prostate for Benign Prostatic Obstruction N/A
Recruiting NCT04288427 - 5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy N/A
Not yet recruiting NCT04245566 - Prostatic Artery Embolization vs. Pharmacotherapy for LUTS/BPH Phase 3
Completed NCT03246880 - Clinical Trial To Evaluate the Efficacy and Safety of CKD-397 in Benign Prostatic Hyperplasia Patients Phase 3
Withdrawn NCT01967251 - Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction Phase 2
Completed NCT02509975 - Safety and Efficacy of OCL 503 in Prostate Artery Embolization N/A
Completed NCT02206243 - Embozene® Microspheres for Prostatic Arterial Embolization in Patients With Symptomatic Benign Prostatic Hyperplasia
Completed NCT02283684 - GreenLight Laser Photoselective Vaporization of the Prostate vs Bipolar Transurethral Vaporization of the Prostate; RCT Phase 4
Completed NCT01438775 - Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) Phase 3
Completed NCT01454349 - Study of PRX302 for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia (BPH) Phase 1/Phase 2
Completed NCT01139762 - A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms Phase 3
Completed NCT01152190 - A Study in Benign Prostatic Hyperplasia Phase 3
Active, not recruiting NCT00400894 - Annexin A3 (ANXA3) as Protein-Based Marker for Non-Invasive Molecular Diagnostics of Prostate Carcinoma N/A
Unknown status NCT00381108 - Study of the Effects of Pomegranate Tablets on Enlarged Prostates Phase 1
Completed NCT00224133 - The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months Phase 3
Completed NCT00701779 - Dutasteride and Flex Dose of Tamsulosin on as Needed Basis, to Treat Benign Prostatic Hyperplasia Phase 4
Terminated NCT02962674 - To Evaluate the Safety and Performance of the ProstaCare Water Electrolysis System in Relieving Symptoms of BPH. N/A
Active, not recruiting NCT05415748 - Deprescribing Tamsulosin in Older Men Phase 4
Recruiting NCT04853914 - Evaluation of the Safety of the Treatment of Benign Prostatic Hyperplasia by High Intensity Focused Ultrasound. N/A